Home Pharmaceuticals Europe Nifedipine Market Trend, Growth to 2022-2030

Europe Nifedipine Market

Select Regional / Country Report

Europe Nifedipine Market Size, Share & Trends Analysis Report By Type (Nifedipine Controlled-Release Tablets, Nifedipine Extended Action Tablets), By Application (Primary Pulmonary Hypertension, Heart Failure, Raynaud’s Syndrome, Cephalalgia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region (North America, Asia-Pacific, Europe, Latin America, The Middle East and Africa) and By Country(U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, Rest of Europ) Forecasts, 2022-2030

Report Code: SRPH3048DR
Study Period 2018-2030 CAGR 8.5%
Historical Period 2018-2020 Forecast Period 2022-2030
Base Year 2021 Base Year Market Size USD XX Billion
Forecast Year 2030 Forecast Year Market Size USD 648.08 Million
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The Europe Nifedipine market size is expected to reach a valuation of USD 648.08 million by 2030, driving at a CAGR of 8.5 % during the forecast period (2022–2030).

Nifedipine is a calcium channel blocker, which means it prevents calcium from passing through the arteries walls. Nifedipine is used to cure high blood pressure, arrhythmias, and angina. Other therapeutic applications include ryanoids syndrome, cephalalgia, and other similar conditions. The market is being driven by a growth in the senior population, healthcare spending, the incidence of chronic conditions such heart failure, arrhythmias, and hypertension, and healthcare awareness. On the other hand, market expansion is hampered by government laws and unfavourable pharmacological consequences like hypotension, stomach ulcers, and congestive heart failure. New development prospects are anticipated to emerge from R&D activities. HBP problems are treated with dihydropyridine calcium channel blockers such nitrendipine and nisoldipine. Premature labour has been more common in recent years, resulting in an increase in demand for the drugs described above. Premature labour is treated with tocolytics, which work by inhibiting muscle contractions. Similarly, nifedipine protects preemies from developing health problems as a result of their premature birth. The global nifedipine market was worth USD 856.66 million in 2020, and is expected to increase to USD 1,792.36 million by 2029, showing an annual growth rate of 8.49% (CAGR).

 The new WHO European Regional Obesity Report 2022, released on 3 May by the WHO Regional Office for Europe, shows that overweight and obesity rates have reached epidemic proportions across the Region and are still rising, with none of the Region's 53 Member States on track to meet the WHO Global Noncommunicable Disease (NCD) target of halting obesity rise by 2025 and owing to this, more diseases are becoming prevalent rising the demand for the nifedipine market in the region.

Market Dynamics

Market Drivers

  • Product demand is expected to increase as demand for calcium channel blocker medications rises: Nifedipine is an effective treatment for different types of illnesses, including high blood pressure (hypertension), heart attack, chilblain, cephalalgia, chest discomfort (angina), preterm labour, prinzmetal's angina (squeezing of blood vessels), and Raynaud's phenomenon (numbness of multiple body regions). The drug's overall consumption is increasing as a result of its effectiveness, particularly in the treatment of premature labour. It suppresses preterm labour by preventing muscle cell contractions, and it aids in the prevention of health problems that preemies are prone to as a result of their premature birth. These factors may drive up demand for calcium channel blockers and nifedipine in the European region.
  • Long-term illnesses are expected to grow in number, boosting product demand: Following COVID-19, the use of calcium channel blockers like Norvasc, Nicardipine, Procardia, and others has increased, resulting in an increase in acute and chronic health problems. People's poor lifestyles are bringing them closer to ailments like high blood pressure, chest aches, heart attacks, and so on. As a result, the overall rate of drug consumption is increasing, which is driving up demand for Nifedipine in Europe.

Market Restraints

  • Health risks associated with nifedipine are expected to stifle market growth: Despite the fact that the demand for nifedipine is increasing, one issue that is expected to stifle its growth is the numerous negative effects connected with its use. Nausea, rapid weight gain, discomfort in various regions of the body, and irregular heartbeat are all symptoms. Furthermore, significant adverse effects include liver damage and breathing cessation. In addition, taking nifedipine with some antibiotics and antiviral medications might cause a spike in nifedipine levels in the body, which can lead to major health problems which could restrict the market growth in European region.

Market Opportunities

  • Favourable government support: Market expansion would be aided by favourable government backing. For example, some countries in the region announced plans to reduce premature deaths from cardiovascular diseases by screening and treating more than 80% of hypertensive patients by the end of 2025, and such initiatives can provide lucrative opportunities for the European market's key players.

Regional Analysis

By 2030, the Europe Nifedipine market is estimated to be worth USD 648.08 million, with a CAGR of 8.5% over the forecast period (2022–2030). The new WHO European Regional Obesity Report 2022, released on May 3 by the WHO Regional Office for Europe, shows that overweight and obesity rates have reached epidemic proportions across the Region and are still rising, with none of the Region's 53 Member States on track to meet the WHO Global Noncommunicable Disease (NCD) target of halting obesity rise by 2025, and as a result, more diseases are becoming prevalent, increasing demand for nifedipine in the resale market.

Obesity is low in France compared to other European countries, but it is on the rise, according to the most recent epidemiological census. In France, obesity has doubled in the last 25 years. A new national epidemiological study on overweight and obesity has been released. Obesity affects 17% of the French population, compared to 15% eight years earlier, accounting for almost 8,567,128 people. Numbers are rising and as a result many diseases are prevalent, which is driving up the use of Nifedipine in the region.

The proportion of the German population aged 65 and up is expected to reach 22% by 2020. This was a significant rise over the previous year, and the share has been steadily increasing year after year. This is a significant proportion of Germany's population ageing, which is likely to continue in the coming years, boosting the use of Nifedipine in the region as elderly people are likely to get affected with some or the other disease.

Report Scope

Report Metric Details
By Type
  1. Nifedipine Controlled-Release Tablets
  2. Nifedipine Extended Action Tablets
By Application
  1. Primary Pulmonary Hypertension
  2. Heart Failure
  3. Raynaud’s Syndrome
  4. Cephalalgia
  5. Others
By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Others
By Region
  1. North America
  2. Asia-Pacific
  3. Europe
  4. Latin America
  5. The Middle East and Africa
Company Profiles AstraZeneca plc Hoffmann-La Roche AG Teva Pharmaceutical Industries Ltd. Vectura Group plc Pfizer Inc. GlaxoSmithKline plc Novartis AG
Geographies Covered
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europ
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The two varieties of nifedipine pills are nifedipine controlled-release tablets and nifedipine extended-action tablets. In 2021, the controlled-release pills of nifedipine had the most market share. Rising rates of hypertension and heart failure, the use of cutting-edge technology in pharmaceutical research, more funding from the government and international organisations, and increased public awareness about the importance of preventative treatment can all be attributed to this significant increase.

Based on the application, the section is divided into primary pulmonary hypertension, heart failure, Raynaud's disease, cephalalgia, and others. Primary pulmonary hypertension was the most common cause of pulmonary hypertension in 2021. Obesity, poor dietary habits, excessive junk food consumption, a lack of exercise, an increase in the younger generation's smoking and alcohol consumption, and stress are all contributors. Expanding government and private sector actions, as well as firm programmes for the development of new medications to treat hypertension and diabetes, are likely to drive this area.

Hospital pharmacies, retail pharmacies, and other distribution channels make up the European nifedipine market. In 2020, hospital pharmacies dominated the market in the region, and it is expected to increase at a quicker CAGR over the forecast period.

Market Size By Type

Market Size By Type
  • Nifedipine Controlled-Release Tablets
  • Nifedipine Extended Action Tablets
  • Recent Developments

    • The supply of 30mg Adalat LA prolonged-release tablets to the United Kingdom was restored in 2021, according to MNC, a German nifedipine manufacturer. The tablets listed above were out of sale in the UK earlier this year due to a scarcity. Manufacturing issues were caused by Alliance healthcare issues, which have been handled for the time being. Furthermore, of the several nifedipine drugs, prolonged-release tablets have proven to be the most effective.

    Key Players

    Europe Nifedipine Market Share of Key Players

    Europe Nifedipine Market Share of Key Players
    AstraZeneca plc Hoffmann-La Roche AG Teva Pharmaceutical Industries Ltd. Vectura Group plc Pfizer Inc. GlaxoSmithKline plc Novartis AG Others

    We are featured on :